JR Rahn

A promising new startup, Ovax Inc., secured $10 million in funding to advance the development of a groundbreaking vaccine designed to prevent fentanyl-related deaths. The initiative focuses on commercializing academic research aimed at preventing the potent opioid from reaching the brain, reported...

Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initial public offering of approximately 14 million of its common shares, ahead of the company’s expected Nasdaq listing. Shares are proposed to go at a price of between $13 and $...

Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co-founder and CEO, would step down. Benzinga spoke with Rahn on what the transition means for MindMed, the industry ...

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after submitting an application to uplist its shares from Toronto’s NEO exchange, MindMed (OTCQB: MMEDF) confirmed it will commence trading on the Nasdaq Capital...

The Horizons Psychedelic Stock Index ETF is now listed on Toronto’s NEO exchange under the symbol ‘PSYK.’ PSYK is the first exchange traded fund providing exposure to the burgeoning industry of medicinal psychedelics. The ETF is managed by Horizons ETFs...

Mind Medicine (MindMed) Inc (OTC: MMEDF), a medicine biotech company in psychedelics, on Wednesday announced its start of the first-ever clinical trial measuring and evaluating 3,4-methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) combinations in the human body, at the...

In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.  The industry grew closer to federal legalization of the first psychedelic compounds for therapeutic use. With scientific, regulatory and corporate developments becoming...

In an exclusive to Benzinga, Mind Medicine (MindMed) Inc (OTC: MMEDF), a leading medicine biotech company in psychedelics, on Tuesday revealed the introduction of a division known as Albert, to help research and develop an integrated platform for delivering psychedelic medicines, experiential...

Psychedelic drug development company MindMed (NEO: MMED) (OTCQB: MMEDF) has submitted an application to cross-list on NASDAQ. MindMed was the first psychedelics company to go public in March of 2020 on the NEO exchange. The company also lists on the Frankfurt Stock Exchange under the symbol...

On Friday, UK-based mental health care company Compass Pathways (NASDAQ: CMPS) announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange. JR Rahn, CEO of psychedelics drug development company Mind...

Biopharmaceutical and psychedelics research company Mind Medicine Inc. (NEO:MMED) (OTC: MMEDF)  announced Thursday that it will begin studying DMT’s effects on humans in a Phase 1 clinical trial conducted in collaboration with University Hospital Basel in Switzerland. Understanding The...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. New Leaf Brands Changes Name To Mydecine, Announces New HQ  Cannabis company NewLeaf...

Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline. The move comes as part of the company’s exclusive collaboration agreement with the University...

Psychedelic pharmaceutical company Mind Medicine (MindMed) Inc. (OTC: MMEDF) (NEO:MMED) says it found an off-switch to end a bad trip. The Toronto-based company announced it has discovered and filed a patent application for a neutralizing agent intended to stop the effects of...